Published in
BioMed Central, Italian Journal of Pediatrics, 1(48), 2022
DOI: 10.1186/s13052-022-01272-z
Links
Tools
Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5–11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP)
,
Mauro Calvani,
Fabio Cardinale,
Riccardo Castagnoli ,
Elena Chiappini,
Claudio Cravidi,
Michele Miraglia Del Giudice ,
Marzia Duse,
Amelia Licari,
Sara Manti,
Alberto Martelli,
Giampaolo Ricci,
Giuseppe Pingitore
and other authors.
Full text: Download
Abstract
AbstractBNT162b2 vaccine, developed by BioNTech and Pfizer ha recently approved for use in children aged 5 to 11 years. Recent data show evidence of safety on the administration and serious adverse events have been rarely reported. However, allergic systemic reactions could occur. In some cases, a correct allergic evaluation allows identifying patients at risk of developing an anaphylactic reaction. Risk assessment of allergic reactions to COVID-19 vaccines is useful to limit contraindications to vaccination and help to safely vaccinate people supposed to be at risk of allergic reactions.